Notably, standard pharmacological treatments for diabesity—such as metformin, sodium/glucose cotransporter 2 (SGLT-2) inhibitors, GLP1-RA, and dipeptidyl peptidase-IV (DPPIV) inhibitors—are effective in managing body weight and glycemic control, contributing to the inhibition of obesity [116,117]. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.